SciClone Pharmaceuticals (Holdings) (HKSE:06600) Forward PE Ratio : 0.00 (As of Jun. 08, 2024)

View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) Forward PE Ratio?

SciClone Pharmaceuticals (Holdings)'s Forward PE Ratio for today is 0.00.

SciClone Pharmaceuticals (Holdings)'s PE Ratio without NRI for today is 9.77.

SciClone Pharmaceuticals (Holdings)'s PE Ratio for today is 9.88.

SciClone Pharmaceuticals (Holdings) Forward PE Ratio Historical Data

The historical data trend for SciClone Pharmaceuticals (Holdings)'s Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals (Holdings) Forward PE Ratio Chart

SciClone Pharmaceuticals (Holdings) Annual Data

Trend

2021-12

2022-12

2023-12

2024-01

Forward PE Ratio

5.32

5.95

9.41

8.54

SciClone Pharmaceuticals (Holdings) Semi-Annual Data
	2021-06	2021-09	2021-12	2022-03	2022-06	2022-09	2022-12	2023-03	2023-06	2023-09	2023-12
Forward PE Ratio	12.00	6.94	5.32	5.38	5.68	4.42	5.95	6.94	6.60	6.90	9.41

Competitive Comparison of SciClone Pharmaceuticals (Holdings)'s Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals (Holdings)'s Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SciClone Pharmaceuticals (Holdings)'s Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals (Holdings)'s Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where SciClone Pharmaceuticals (Holdings)'s Forward PE Ratio falls into.

SciClone Pharmaceuticals (Holdings) Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

SciClone Pharmaceuticals (Holdings) Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Forward PE Ratio

Traded in Other Exchanges

N/A

Address

381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN

Website

https://www.sciclone.com

SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.

Executives

Ubs Group Ag	2201 Interest of corporation controlled by you
Zhao Hong	2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang	2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited	2501 Other
Ascendent Capital Partners Ii Gp Limited	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p.	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p.	2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited	2101 Beneficial owner
Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Bank Of China Limited	2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited	2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines